From the blog

Epigenetics Used to Improve Immunotherapy for Mesothelioma

Researchers are looking into changing mesothelioma cells to make them more susceptible to immunotherapy. Mesothelioma is a hard cancer to treat, so new approaches need to be developed to try to lengthen and improve mesothelioma patients’ lives. Immunotherapy can work well for some, but for others it does very little,[…]

Read More »

LMB-100 and Ipilumab Combination Being Tested for Pleural and Peritoneal Mesothelioma

The National Cancer Institute just started a study to see if it could make immunotherapy more potent for treating mesothelioma. The study combines a manmade protein that kills cancer cells called LMB-100 and an immunotherapy drug called ipilumab. The problem with current immunotherapy treatments is they do not work well[…]

Read More »

GPX-1 Could be used as a Biomarker for Mesothelioma

An enzyme that helps clean up the byproducts of cellular oxidation could potentially be a biomarker for pleural mesothelioma. People with very small amounts of the enzyme were found to survive longer than people who have higher levels of the enzyme. The enzyme is Glutathione peroxidase-1 (GPX-1). It can be[…]

Read More »

UCARTMESO CAR-T Cell Therapy Can Help Kill Mesothelioma Cells

A new treatment utilizing CAR-T cell therapy could help prevent mesothelioma cells from protecting themselves. The treatment, called UCARTMESO, is being developed by the French biopharmaceutical company Cellectis. The treatment works by targeting cells that overexpress mesothelin, which is an antigen that prevents cells from sending immune suppressive signals. A[…]

Read More »

Durvalumab and Chemotherapy Extends Mesothelioma Patients’ Lives

Studies are showing that the immunotherapy drug durvalumab can make chemotherapy more effective for treating mesothelioma. Durvalumab is an immunotherapy drug called an immune checkpoint inhibitor. It blocks the protein PD-1, which is used by mesothelioma cells to protect themselves. Researchers believed that if the protein was blocked, mesothelioma cells[…]

Read More »

A Mesothelioma Blood Test Could Improve Patient Quality of Life

A blood test for mesothelioma could help increase the time between CT scan appointments. The typical way doctors test to see if a treatment is working is called mRECIST, which utilizes CT scans and other measurements. CT scans are expensive though and can lead to larger exposure to ionizing radiation[…]

Read More »

Follow Up Care for Mesothelioma

Follow-up care is crucial for treating mesothelioma patients. A study out of the United Kingdom found that when patients receive follow-up care, more input from their caregivers, continuity, and more timely information was necessary. The study involved three National Health Service facilities in England. Two of the centers were secondary[…]

Read More »

SQAP Used Alongside Radiation to Treat Mesothelioma

A chemical that makes cancer cells more sensitive to radiation could potentially help patients with mesothelioma. Radiotherapy utilizes ionizing radiation to damage the DNA of cancer cells, which affects their ability to reproduce and form tumors. Radiation is not always used for mesothelioma patients because mesothelioma cells can be immune[…]

Read More »

Researchers Could Target Neuron Cells to Fight Mesothelioma

Researchers have potentially found a new way to treat cancer by targeting nerve cells.  Researchers at Technion, the Israel Institute of Technology, conducted the study that is now published in the Science Advances journal. The research targets neurons, which promote tumor growth. The researchers assumed that once tumor nerve cells[…]

Read More »

Quinacrine Combined with Cisplatin Can Help Fight Mesothelioma Cancer Cells

Mesothelioma patients with a gene mutation could benefit greatly from using an anti-malaria drug called quinacrine. Quinacrine is known by the brand name Atabrine. For a long time, it was the primary anti-malaria drug, but it has been replaced by the preferred chloroquine. Researchers at Penn State found that quinacrine[…]

Read More »